AbGenomics International, Inc. - Product Pipeline Review - 2015

Date: March 26, 2015
Pages: 30
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A9DB1BD16BBEN
Leaflet:

Download PDF Leaflet

AbGenomics International, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘AbGenomics International, Inc. - Product Pipeline Review - 2015’, provides an overview of the AbGenomics International, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AbGenomics International, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of AbGenomics International, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AbGenomics International, Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AbGenomics International, Inc.’s pipeline products
Reasons to buy
  • Evaluate AbGenomics International, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AbGenomics International, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AbGenomics International, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AbGenomics International, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AbGenomics International, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AbGenomics International, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
AbGenomics International, Inc. Snapshot
AbGenomics International, Inc. Overview
Key Information
Key Facts
AbGenomics International, Inc. - Research and Development Overview
Key Therapeutic Areas
AbGenomics International, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
AbGenomics International, Inc. - Pipeline Products Glance
AbGenomics International, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
AbGenomics International, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
AbGenomics International, Inc. - Drug Profiles
AbGn-168H
Product Description
Mechanism of Action
R&D Progress
AbGn-7
Product Description
Mechanism of Action
R&D Progress
AbGn-107
Product Description
Mechanism of Action
R&D Progress
AbGn-108
Product Description
Mechanism of Action
R&D Progress
AbGn-109
Product Description
Mechanism of Action
R&D Progress
AbGn-110
Product Description
Mechanism of Action
R&D Progress
AbGn-122
Product Description
Mechanism of Action
R&D Progress
AbGenomics International, Inc. - Pipeline Analysis
AbGenomics International, Inc. - Pipeline Products by Target
AbGenomics International, Inc. - Pipeline Products by Route of Administration
AbGenomics International, Inc. - Pipeline Products by Molecule Type
AbGenomics International, Inc. - Pipeline Products by Mechanism of Action
AbGenomics International, Inc. - Recent Pipeline Updates
AbGenomics International, Inc. - Dormant Projects
AbGenomics International, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

AbGenomics International, Inc., Key Information
AbGenomics International, Inc., Key Facts
AbGenomics International, Inc. - Pipeline by Indication, 2015
AbGenomics International, Inc. - Pipeline by Stage of Development, 2015
AbGenomics International, Inc. - Monotherapy Products in Pipeline, 2015
AbGenomics International, Inc. - Phase II, 2015
AbGenomics International, Inc. - Phase I, 2015
AbGenomics International, Inc. - Preclinical, 2015
AbGenomics International, Inc. - Pipeline by Target, 2015
AbGenomics International, Inc. - Pipeline by Route of Administration, 2015
AbGenomics International, Inc. - Pipeline by Molecule Type, 2015
AbGenomics International, Inc. - Pipeline Products by Mechanism of Action, 2015
AbGenomics International, Inc. - Recent Pipeline Updates, 2015
AbGenomics International, Inc. - Dormant Developmental Projects, 2015
AbGenomics International, Inc., Other Locations

LIST OF FIGURES

AbGenomics International, Inc. - Pipeline by Top 10 Indication, 2015
AbGenomics International, Inc. - Pipeline by Stage of Development, 2015
AbGenomics International, Inc. - Monotherapy Products in Pipeline, 2015
AbGenomics International, Inc. - Pipeline by Top 10 Target, 2015
AbGenomics International, Inc. - Pipeline by Top 10 Route of Administration, 2015
AbGenomics International, Inc. - Pipeline by Top 10 Molecule Type, 2015
AbGenomics International, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


FibroGen, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 May, 2015 · 39 pages

Ask Your Question

AbGenomics International, Inc. - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: